A prospective randomized toxicity study to compare reduced-intensity and myeloablative conditioning in patients with myeloid leukaemia undergoing allogeneic haematopoietic stem cell transplantation
Version of Record online: 25 MAR 2013
© 2013 The Association for the Publication of the Journal of Internal Medicine
Journal of Internal Medicine
Volume 274, Issue 2, pages 153–162, August 2013
How to Cite
Karolinska University Hospital Huddinge, Karolinska Institutet, Stockholm, Sweden A prospective randomized toxicity study to compare reduced-intensity and myeloablative conditioning in patients with myeloid leukaemia undergoing allogeneic haematopoietic stem cell transplantation. J Intern Med 2013; 274: 153–162., , , , , , , , , , ,
- Issue online: 12 JUL 2013
- Version of Record online: 25 MAR 2013
- Accepted manuscript online: 21 FEB 2013 02:59PM EST
- Swedish Cancer Society. Grant Numbers: CAN 2008/562, 10 0333
- Children's Cancer Foundation. Grant Numbers: PROJ09/093, PROJ 09/014
- Swedish Research Council. Grant Number: K2008-64X-05971-28-3
- Cancer Society in Stockholm
- Karolinska Institutet
- 1Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 2003; 101: 1620–9., , et al.
- 3Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 2005; 19: 2304–12., , et al.
- 8Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J Clin Oncol 2005; 23: 9387–93., , et al.
- 14Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood 2003; 102: 1232–40., , et al.
- 15WHO. WHO Handbook for Reporting Results of Cancer Treatment. Geneva: World Health Organization, 1979.
- 17NCI. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Cancer Therapy Evaluation Program. March 31, 2003. (http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf). [accessed 14 March 2013].
- 22Conditioning associated effects on oral mucosa and salivary function in allogeneic hematopoietic stem cell recipients. Thesis, Karolinska Institutet, Stockholm, Sweden, 2011..